Sodium Valproate and the Fetus: A Case Study and Review of the Literature
Sodium valproate is a teratogen responsible for a wide range of abnormalities, including neural tube defects. It has traditionally been prescribed for epilepsy, but is increasingly used for such psychiatric conditions as bipolar disease. Women of childbearing age taking valproate should be warned of its teratogenicity and advised to plan pregnancies, take a higher dose of folate, discuss reducing the dose of valproate or changing the medication with their physician, and have antenatal screening. After birth, the infant should be examined for a wide range of reported abnormalities. Neurodevelopmental assessment should continue throughout childhood. We present a case that illustrates the need for better education of mothers taking valproate and the medical staff prescribing it.
Document Type: Research Article
Publication date: 2009-11-01
- Neonatal Network®, established in April 1981, is a peer-reviewed journal dedicated to assisting neonatal nurses and related health care professionals remain current in their fields. Neonatal Network® acts as a vehicle for the exchange of information by providing up-to-date, relevant articles in the areas of evidence-based clinical practice, research, and education.
Neonatal Network® is issued six times a year; January/February, March/April, May/June, July/August, September/October, and November/December. With a circulation of 10,000, Neonatal Network® goes to more than 1,000 recognized Level II and Level III neonatal intensive care units in the United States.
Academy of Neonatal Nursing Free Access to Journal Contents Online
- Information for Authors
- Subscribe to this Title
- Information for Advertisers
- Academy of Neonatal Nursing Membership Information
- Academy of Neonatal Nursing Free Access to Journal Contents Online
- Request a Sample Issue
- Ingenta Connect is not responsible for the content or availability of external websites